Beijing Kexing Zhongwei

Beijing Kexing Zhongwei Biotechnology, commonly known as Sinovac Life Sciences, is a core subsidiary of Sinovac Biotech Ltd. focused on the development and production of human vaccines. The company is most recognized for developing CoronaVac, an inactivated SARS-CoV-2 vaccine that became one of the most widely used COVID-19 vaccines globally during the pandemic. Beyond its COVID-19 response, the company produces a range of WHO-prequalified products, including vaccines for hepatitis A, enterovirus 71, and seasonal influenza. Sinovac Life Sciences operates advanced manufacturing facilities in Beijing, including high-containment Biosafety Level 3 (BSL-3) labs. The company has attracted significant private investment, notably from Sino Biopharmaceutical, to expand its production capacity and R&D pipeline. Its strategic focus remains on infectious disease prevention through traditional inactivated and next-generation vaccine modalities.